BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 36511318)

  • 1. Investigating N-arylpyrimidinamine (NAPA) compounds as early-stage inhibitors against human cytomegalovirus.
    Parsons AJ; Ophir SI; Gardner TJ; Paredes JC; Stein KR; Kwasny SM; Cardinale SC; Torhan M; Prichard MN; James SH; Atanasoff KE; G-Dayanandan N; Bowlin TL; Opperman TJ; Tortorella D
    Antiviral Res; 2023 Jan; 209():105474. PubMed ID: 36511318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New inhibitors of cytomegalovirus replication: in vitro evaluation, mechanism of action, and in vivo activity.
    Neyts J; De Clercq E
    Verh K Acad Geneeskd Belg; 1994; 56(6):561-92. PubMed ID: 7892749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Convallatoxin-Induced Reduction of Methionine Import Effectively Inhibits Human Cytomegalovirus Infection and Replication.
    Cohen T; Williams JD; Opperman TJ; Sanchez R; Lurain NS; Tortorella D
    J Virol; 2016 Dec; 90(23):10715-10727. PubMed ID: 27654292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ganciclovir. An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients.
    Noble S; Faulds D
    Drugs; 1998 Jul; 56(1):115-46. PubMed ID: 9664203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Synthesis and Anti-Cytomegalovirus Activity of Piperidine-4-Carboxamides.
    Guo X; Ghosh AK; Keyes RF; Peterson F; Forman M; Meyers DJ; Arav-Boger R
    Viruses; 2022 Jan; 14(2):. PubMed ID: 35215828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytomegalovirus infection in transplant recipients: newly approved additions to our armamentarium.
    Khawaja F; Spallone A; Kotton CN; Chemaly RF
    Clin Microbiol Infect; 2023 Jan; 29(1):44-50. PubMed ID: 35843567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral valganciclovir: a new option for treatment of cytomegalovirus infection and disease in immunocompromised hosts.
    Reusser P
    Expert Opin Investig Drugs; 2001 Sep; 10(9):1745-53. PubMed ID: 11772283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiviral treatment of cytomegalovirus infection.
    Ahmed A
    Infect Disord Drug Targets; 2011 Oct; 11(5):475-503. PubMed ID: 21827432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Mutations in the
    Demin MV; Tikhomirov DS; Biderman BV; Drokov MY; Sudarikov AB; Tupoleva TA; Filatov FP
    Vopr Virusol; 2022 Mar; 67(1):37-47. PubMed ID: 35293187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel decay dynamics revealed for virus-mediated drug activation in cytomegalovirus infection.
    Rose J; Emery VC; Kumar D; Asberg A; Hartmann A; Jardine AG; Bignamini AA; Humar A; Neumann AU
    PLoS Pathog; 2017 Apr; 13(4):e1006299. PubMed ID: 28406982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New developments in the management of cytomegalovirus infection after solid organ transplantation.
    Eid AJ; Razonable RR
    Drugs; 2010 May; 70(8):965-81. PubMed ID: 20481654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk Factors and Outcomes of Ganciclovir-Resistant Cytomegalovirus Infection in Solid Organ Transplant Recipients.
    Fisher CE; Knudsen JL; Lease ED; Jerome KR; Rakita RM; Boeckh M; Limaye AP
    Clin Infect Dis; 2017 Jul; 65(1):57-63. PubMed ID: 28369203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brincidofovir (CMX-001) for refractory and resistant CMV and HSV infections in immunocompromised cancer patients: A single-center experience.
    El-Haddad D; El Chaer F; Vanichanan J; Shah DP; Ariza-Heredia EJ; Mulanovich VE; Gulbis AM; Shpall EJ; Chemaly RF
    Antiviral Res; 2016 Oct; 134():58-62. PubMed ID: 27582067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Investigation of Ganciclovir Resistance in Cytomegalovirus Strains Obtained from Immunocompromised Patients].
    Coşkun A; Gökahmetoğlu S; Özmen P; Çevik Ş; Karakükçü M; Kaynar L; Midilli K; Kuşkucu MA
    Mikrobiyol Bul; 2020 Oct; 54(4):619-628. PubMed ID: 33107291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early onset of ganciclovir-resistant cytomegalovirus infection in a lung-transplant recipient.
    Chen F; Bando T; Hanaoka N; Fukuse T; Hasegawa S; Wada H
    Jpn J Thorac Cardiovasc Surg; 2005 Oct; 53(10):562-4. PubMed ID: 16279588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emergence and persistence of multiple antiviral-resistant CMV strains in a highly immunocompromised child.
    Iwasenko JM; Scott GM; Ziegler JB; Rawlinson WD
    J Clin Virol; 2007 Oct; 40(2):152-5. PubMed ID: 17698411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cytomegalovirus infection in transplant recipients].
    Gondo H
    Nihon Rinsho; 1998 Jan; 56(1):173-8. PubMed ID: 9465685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subtherapeutic ganciclovir (GCV) levels and GCV-resistant cytomegalovirus in lung transplant recipients.
    Gagermeier JP; Rusinak JD; Lurain NS; Alex CG; Dilling DF; Wigfield CH; Love RB
    Transpl Infect Dis; 2014 Dec; 16(6):941-50. PubMed ID: 25491023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistent Primary Cytomegalovirus Infection After Deceased Donor Kidney Transplant: Ganciclovir Susceptibility of Human Cytomegalovirus With UL97 D605E Mutation: A Case Report.
    Nawashiro Y; Shiraki K; Yamamoto S; Takizawa K; Sasada Y; Suehiro M; Miura K; Hattori M; Daikoku T; Hisano M
    Transplant Proc; 2018 Dec; 50(10):3932-3936. PubMed ID: 30577289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytomegalovirus infection after liver transplantation: current concepts and challenges.
    Razonable RR
    World J Gastroenterol; 2008 Aug; 14(31):4849-60. PubMed ID: 18756591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.